Press Releases

Found 223 Results
Page 1 of 23

Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.


Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

11/05/2019



Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000


The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]

Tags:

10/17/2019


Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]

Tags:

10/15/2019


Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform


This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]

Tags:

10/14/2019


Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy


  Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]

Tags:

09/18/2019


Onxeo to Attend Key Investor and Scientific Conferences


Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]

Tags:

09/11/2019


Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update


Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, […]

Tags:

07/25/2019


The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation


Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or […]

Tags:

07/01/2019


Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase


OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation […]

Tags:

06/20/2019


Page 1 of 23

Last updated on